Chronic Kidney Disease: Emerging Mechanisms, Consequences and Targeted Treatments (M2)
April 12-15, 2026
| Fairmont Hotel Vancouver, Vancouver, BC, Canada
Matthias Kretzler, Hiddo Lambers Heerspink, Olga G. Troyanskaya and Maria Chiara Magnone
Scholarship Deadline: Dec. 10, 2025 | Abstract Deadline: Mar. 20, 2026 | Early Registration Deadline: Feb. 12, 2026
| 4:00–8:00 PM |
Registration |
British/Columbia Foyer |
| 6:00–8:00 PM |
Welcome Mixer |
British/Columbia Foyer |
| 7:30–8:30 AM |
Breakfast |
Vancouver Island Room |
| 8:30–10:00 AM |
Welcome and Keynote Address |
British Ballroom |
| |
Griffin P. Rodgers, National Institute of Diabetes, Digestive and Kidney Diseases
Building the Village of Precision Medicine for Kidney Disease: NIDDK Vision for CKD in 2026 |
|
| 10:00–10:20 AM |
Coffee Break |
British/Columbia Foyer |
| 10:20–11:45 AM |
CKD Function and Failure; From Models to Man |
British Ballroom |
| |
Melissa Hallow, University of Georgia
Modelling Kidney Function: What Renal Physiology Teaches us in 2025 for CKD: Lessons Learned from Modeling Endothelin Function in CKD Trials |
|
| |
Samira Musah, Duke University
Kidney Tissue Bioengineering for Patient Level Precision Medicine |
|
| |
Jonathan Himmelfarb, Mount Sinai School of Medicine
Ex vivo Organ Cross Talk: Liver-Kidney System Defines Molecular Cross Talk in Toxin Induced CKD |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 11:45–1:00 PM |
Poster Setup |
British/Columbia Ballroom |
| 11:45–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
British/Columbia Ballroom |
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
British Ballroom |
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
British/Columbia Foyer |
| 5:00–7:00 PM |
Unraveling the Molecular Machinery of the Nephron in Function and Failure |
British Ballroom |
| |
Laura Barisoni, Duke University
Tissue is the Issue: AI Driven Image Analysis Maps Structural and Molecular Disease Trajectories |
|
| |
Katalin Susztak, University of Pennsylvania
From Mapping to Mechanism to Medicine |
|
| |
Olga G. Troyanskaya, Princeton University
Genes and Environment Driving CKD: Linking Environmental Exposures with Genetic Risk Assessment to Guide CKD Management |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
Vancouver Island Room |
| 7:30–10:00 PM |
Poster Session 1 |
British/Columbia Ballroom |
| 7:30–8:30 AM |
Breakfast |
Vancouver Island Room |
| 8:00–8:30 AM |
Poster Setup |
British/Columbia Ballroom |
| 8:15–5:00 PM |
Poster Viewing |
British/Columbia Ballroom |
| 8:30–11:30 AM |
CKD in Obesity and Diabetes: Driving the Disease Burden in the Cardio Metabolic Pandemic |
British Ballroom |
| |
Tamer Coskun, Eli Lilly & Company
Obesity Driven Metabolic Reprogramming: From Metabolic Profiling to Drug Targets for Cardiorenal Disease |
|
| |
Katherine R. Tuttle, University of Washington
Finally Breaking the Death Spiral of CKD: Mechanistic Trials Defining the Mode of Action of the Incretin System |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
British/Columbia Foyer |
| 11:30–12:30 PM |
Lunch |
Vancouver Island Room |
| 12:00–2:30 PM |
Poster Session 2 |
British/Columbia Ballroom |
| 4:30–5:00 PM |
Coffee Available |
British/Columbia Foyer |
| 5:00–7:00 PM |
Primary Glomerular Diseases Driving CKD: Insight into a Rapidly Evolving Targeted Therapy Landscape |
British Ballroom |
| |
Brad H Rovin, Ohio State University College of Medicine
Innate Immunity Modulation in Lupus Nephritis, Bringing Insight from Trials Back to the Bench |
|
| |
Chee Kay Cheung, University of Leicester
The Right Drug for the Right IgAN in 2025: Impact of Endothelin Blockade on Glomerular Manifestations of IgA Nephritis |
|
| |
Tobias B Huber, University Medical Center Hamburg-Eppendorf
Understanding Filtration Barrier Failure Drives Novel Treatments in Nephrotic Syndrome |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
On Own for Dinner |
|
Wednesday, April 15, 2026
| 7:30–8:30 AM |
Breakfast |
Vancouver Island Room |
| 8:30–11:30 AM |
Genes and Kidney; Unique Opportunities for Targeted Therapies, Lessons Learned from ApoL1 and Beyond |
British Ballroom |
| |
Whitney Besse, Yale School of Medicine
Polycystic Kidney Disease: The Journey from Gene to Therapies |
|
| |
Martin Pollak, Beth Israel Deaconess Medical Center
ApoL1 Biology and Kidney Disease |
|
| |
Akinlolu Ojo, University of Kansa
ApoL1 across Continents: Lessons Learned on Gene Environment Interaction in H3 Africa KDRN |
|
| |
Glenn Chertow, Stanford University
Lessons Learned from the First Trials Targeting ApoL1 Kidney Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
British/Columbia Foyer |
| 11:30–5:00 PM |
On Own for Lunch |
|
| 1:00–2:00 PM |
Panel: Perspectives: Personalized Medicine and Patient-Centered Strategies (joint) |
British Ballroom |
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
British Ballroom |
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
British/Columbia Foyer |
| 5:00–6:45 PM |
Precision Clinical Trial Strategies for Kidney Disease |
British Ballroom |
| |
Matthias Kretzler, University of Michigan
Lessons Learned from Matching Patients Renal Pathobiology to Targeted Therapies in Glomerular Disease |
|
| |
Maria Chiara Magnone, Janssen Inc.
Platform Trials in CKD, State of the Art in 2026 |
|
| |
Hiddo Lambers Heerspink, University Medical Center Groningen
Precision Medicine Trials in CKD: Bringing Molecular Understanding of CKD Drugs to Clinical Care |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
British Ballroom |
| 7:00–8:00 PM |
Social Hour with Dinner |
Vancouver Island Room |
| 8:00–11:00 PM |
Entertainment |
|
